Published randomized trials of MDR1/PGP modulation.
| Trial/Pts . | Modulating agent/dose . | Chemotherapy . | Patients . | Principal Findings . |
|---|---|---|---|---|
| List et al7 | CSA/16 mg/kg/day | Ara-C Daunorubicin (cont. infusion) | 226 | CSA improved survival |
| Liu Yin et al21 | CSA/5-10 mg/kg/day | Daunorubicin (bolus), Ara-C, Etoposide | 235 | Survival worse with CSA in pts over age 60 |
| Greenberg et al26 | PSC 833 10 mg/kg/day | Mitoxantrone, Etoposide, Ara-C | 113 | No effect of PSC 833 |
| Baer et al27 | PSC 833 10 mg/kg/day | Daunorubicin, Ara-C, Etoposide | 120 | Higher early death rate with PSC |
| Trial/Pts . | Modulating agent/dose . | Chemotherapy . | Patients . | Principal Findings . |
|---|---|---|---|---|
| List et al7 | CSA/16 mg/kg/day | Ara-C Daunorubicin (cont. infusion) | 226 | CSA improved survival |
| Liu Yin et al21 | CSA/5-10 mg/kg/day | Daunorubicin (bolus), Ara-C, Etoposide | 235 | Survival worse with CSA in pts over age 60 |
| Greenberg et al26 | PSC 833 10 mg/kg/day | Mitoxantrone, Etoposide, Ara-C | 113 | No effect of PSC 833 |
| Baer et al27 | PSC 833 10 mg/kg/day | Daunorubicin, Ara-C, Etoposide | 120 | Higher early death rate with PSC |